Rhamnazin (200 mg/kg; i.g.; daily for 25 days) inhibits breast cancer growth and angiogenesis in mice[1].
Rhamnazin (5-20 mg/kg; i.p.; once) shows strong antioxidant and anti-inflammatory properties in the rat acute lung injury model[2].
| Animal Model: | BALB/c nude mice, breast cancer xenograft model[1] |
| Dosage: | 200 mg/kg |
| Administration: | Intragastric administration, daily for 25 days |
| Result: | Dramatically suppressed tumor volumes by 47% compared with the vehicle group. Showed a significant reduction of pVEGFR2Tyr951-positive cells in tumors. Resulted in downregulation of VEGFR2 downstream molecules phosphorylation including MAPK, AKT and STAT3. |
